Chunli Medical: Net profit expected to increase by 118.1% year-on-year to 273 million yuan by 2025, actively expanding into international markets

robot
Abstract generation in progress

Recently, Chunli Medical released its 2025 annual report. The company’s operating revenue was 1.05 billion yuan, up 29.8% year over year; net profit attributable to shareholders was 273 million yuan, up 118.1% year over year; net profit attributable to shareholders after deducting non-recurring items was 256 million yuan, up 170.3% year over year; net operating cash flow was 405 million yuan, up 21,412.4% year over year; EPS (fully diluted) was 0.7105 yuan.

In its 2025 annual report, the company stated that in terms of its operating business, it mainly focuses on the research, development, production, and sales of orthopedic medical devices, and has continued to maintain a leading market position in this field. During the reporting period, the company actively expanded into international markets, increased the promotion of its export business, and drove overall sales growth.

The company’s innovation and diversified layout across its product lines includes the development of new products such as orthopedic surgical robots, sports medicine, and PRP. In addition, the company also emphasized its strategic layout in the high-value orthopedic implant consumables segment, aiming to further enhance its competitiveness through technological innovation and market expansion.

(Chunli Medical)

(Editor: Yang Yan, Lin Chen)

Key words:

                                                            Medical
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin